Abstract
To evaluate what determines the increase in quality of life during treatment for ADHD: improvement in core ADHD symptoms or improvement in global psychopathology ratings. A prospective follow-up of ADHD patients in one community clinic. Standardized evaluation and outcome measures were used, including the Mini International Neuropsychiatric Interview, Child Symptom Inventory, 18 item ADHD rating scale, and the Health and Life Functioning Scale. 75 patients between the ages of 6 and 12 were treated with atomoxetine or stimulants with a stable dose for 10months. At end point, there were modest improvements in ADHD symptoms, global psychopathology, level of functioning and quality of life. The improvement in quality of life was driven by a decrease in global psychopathology, not by a decrease in ADHD symptoms. The treatment for ADHD may need to be broadened beyond the core symptoms. A chronic disease management model may well be applicable.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
